DRUGS group Acambis may attempt to develop a vaccine for Sars. Ten governments, led by the US, have bought its smallpox vaccine. The US order helped Acambis (up 9 1/2p to 296p) to first-quarter profits of £9.5m, from a £2.8m loss last time.
Create a FREE account to continue reading
Registration is a free and easy way to support our journalism.
Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.
Thank you for registering
Please refresh the page or navigate to another page on the site to be automatically logged in